The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.

The LLSC is also pleased to announce a new research funding partnership with AstraZeneca Canada to co-fund two (2) grants in this competition. AstraZeneca is a global, innovation-driven biopharmaceutical business with a focus on the discovery, development, and commercialization of medicines that transform lives. In addition to bringing life-changing medicines to patients, AstraZeneca Canada is committed to supporting research that helps to better understand the complexities of cancers. As such, AstraZeneca Canada is partnering with the LLSC to drive Canadian research that aims to strengthen the understanding, diagnosis and treatment of blood cancers to help improve patient outcomes.

The LLSC is also partnered with Myeloma Canada to fund one (1) grant in this competition.  Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. The organization is driven to improve the lives of those affected by myeloma by empowering the community through awareness, education and advocacy programs, and supporting clinical research to find a cure. Since it was founded in 2005, Myeloma Canada has been making myeloma matter. Applications relating to the treatment of multiple myeloma should aim to accelerate the development of Canadian academic cellular therapies.

The LLSC is pleased to  continue our partnership with the Cancer Research Society (CRS) to co-fund five (5) Operating Grants in this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.